Bioavailability, Safety, and Tolerability of BIS-001 ER
Status:
Completed
Trial end date:
2017-09-30
Target enrollment:
Participant gender:
Summary
This study investigates the safety, tolerability, and pharmacokinetics of BIS-001 ER in
healthy volunteers. Subjects will be dosed twice daily, with a dose escalation occurring
every 2-3 days until a maximum dose of 5mg per day is reached.
Phase:
Phase 1
Details
Lead Sponsor:
Biscayne Neurotherapeutics, Inc. Supernus Pharmaceuticals, Inc.